Back to Search
Start Over
Modified Glasgow Prognostic Score as a Prognostic Factor in Patients with Extensive Disease-Small-Cell Lung Cancer: A Retrospective Study in a Single Institute
- Source :
- Chemotherapy. 64:129-137
- Publication Year :
- 2019
- Publisher :
- S. Karger AG, 2019.
-
Abstract
- Introduction: Small-cell lung cancer (SCLC) is a very chemosensitive solid tumor but is characterized by rapid progression. The modified Glasgow prognostic score (mGPS) has been shown to be an independent prognostic factor in various tumors. However, there have been few reports regarding the prognostic value of mGPS in extensive disease (ED)-SCLC. Objective: This study was designed to clarify the clinical significance of mGPS focusing on its usefulness as a prognostic indicator for the survival and serial administrations of chemotherapies in patients with ED-SCLC. Methods: We retrospectively analyzed the clinical records of ED-SCLC patients diagnosed and treated at Shinshu University School of Medicine between January 2005 and December 2018. Overall survival (OS) was compared according to mGPS and we examined whether mGPS could be a prognostic factor in ED-SCLC using the Kaplan-Meier method and univariate and multivariate Cox hazard analyses. Results: Eighty-three patients were enrolled in this study. The median OS of mGPS 0, mGPS 1, and mGPS 2 groups were 13.6, 9.2, and 5.7 months, respectively. The OS of the mGPS 0 group was significantly longer than those of mGPS 1 and mGPS 2 groups (log-rank, p = 0.025 and 0.008, respectively). The rates of second-line chemotherapy administration in mGPS 0, mGPS 1, and mGPS 2 groups were 79.4, 61.9, and 33.3%, respectively. The rate in the mGPS 0 group was significantly higher than that in the mGPS 2 group (p = 0.003). Multivariate analyses indicated that mGPS 2 was an independent unfavorable prognostic factor in addition to old age (≥75 years), poor performance status (2–3), and elevated serum lactate dehydrogenase level (≥223 IU/L). Conclusion: In ED-SCLC patients, mGPS was useful as a prognostic indicator for OS.
- Subjects :
- Adult
Male
0301 basic medicine
Oncology
Prognostic factor
medicine.medical_specialty
Lung Neoplasms
Multivariate analysis
medicine.medical_treatment
030106 microbiology
Kaplan-Meier Estimate
03 medical and health sciences
0302 clinical medicine
Internal medicine
Antineoplastic Combined Chemotherapy Protocols
Drug Discovery
medicine
Humans
Pharmacology (medical)
Clinical significance
In patient
Lung cancer
Aged
Neoplasm Staging
Proportional Hazards Models
Retrospective Studies
Aged, 80 and over
Pharmacology
Chemotherapy
Extensive Disease
business.industry
Retrospective cohort study
General Medicine
Middle Aged
Prognosis
medicine.disease
Small Cell Lung Carcinoma
Infectious Diseases
030220 oncology & carcinogenesis
Female
business
Subjects
Details
- ISSN :
- 14219794 and 00093157
- Volume :
- 64
- Database :
- OpenAIRE
- Journal :
- Chemotherapy
- Accession number :
- edsair.doi.dedup.....faca5b716dc3569dd3c2055bccab6582